Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Sep 22, 2017 03:36PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Bear.
Yes, completion of BoM, various orphan trials at RVX and continued development at Zenith.
My apologies. I have mixed up the companies in my response and I should be more precise.
Toinv